PMID- 35966517
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220816
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 9
DP  - 2022
TI  - High-flow arteriovenous fistula and myocardial fibrosis in hemodialysis patients 
      with non-contrast cardiac magnetic resonance imaging.
PG  - 922593
LID - 10.3389/fcvm.2022.922593 [doi]
LID - 922593
AB  - BACKGROUND: The role of high-flow arteriovenous fistula (AVF) in cardiovascular 
      morbidity in hemodialysis (HD) patients is very likely under-recognized. We 
      assessed the relationship between high access flow (Qa) and myocardial fibrosis 
      in HD patients. METHODS: Myocardial fibrosis was assessed by native T1 relaxation 
      times on non-contrast cardiac magnetic resonance imaging and a potential marker 
      of fibrosis. Serum levels of galectin-3, N-terminal pro-B-type natriuretic 
      peptide (NT-proBNP), and monocyte chemoattractant protein 1 (MCP-1) were measured 
      in 101 HD patients who underwent regular monitoring of AVF Qa. A high-flow AVF 
      was defined as a Qa >2 L/min. RESULTS: Hemodialysis patients showed significantly 
      higher galectin-3 value and increased T1 relaxation time compared to healthy 
      volunteers, suggesting increased myocardial fibrosis in uremic cardiomyopathy. In 
      HD patients, 20 (19.8%) had a Qa > 2L/min, and they had significantly higher 
      cardiac output, cardiac index, left ventricular mass, and increased T1 times than 
      those with a Qa </= 2 L/min. Also, serum galectin-3 and NT-proBNP levels were much 
      higher in the high Qa group, indicating a close relationship between the high Qa, 
      increased myocardial fibrosis, and the risk of heart failure (HF) in HD patients. 
      It is interesting that a higher AVF Qa for myocardial fibrosis was independent of 
      several traditional cardiovascular risk factors as well as serum levels of 
      NT-proBNP and MCP-1. CONCLUSIONS: A supra-physiologically high Qa can be related 
      to myocardial fibrosis and increased risk of HF in HD patients. Regular Qa 
      monitoring could allow early detection of a high-flow AVF that could arise 
      cardiac complications.
CI  - Copyright (c) 2022 Choi, Lee, An, Song, Kim, Lee and Kim.
FAU - Choi, Yong Seon
AU  - Choi YS
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
FAU - Lee, In Jae
AU  - Lee IJ
AD  - Department of Radiology, Hallym University Sacred Heart Hospital, Anyang, South 
      Korea.
FAU - An, Jung Nam
AU  - An JN
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
FAU - Song, Young Rim
AU  - Song YR
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
FAU - Kim, Sung Gyun
AU  - Kim SG
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
FAU - Lee, Hyung Seok
AU  - Lee HS
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
FAU - Kim, Jwa-Kyung
AU  - Kim JK
AD  - Department of Internal Medicine & Kidney Research Institute, Hallym University 
      Sacred Heart Hospital, Anyang, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20220727
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC9363608
OTO - NOTNLM
OT  - access flow
OT  - cardiac fibrosis
OT  - galectin-3
OT  - hemodialysis
OT  - native T1
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/16 06:01
PMCR- 2022/01/01
CRDT- 2022/08/15 03:43
PHST- 2022/04/28 00:00 [received]
PHST- 2022/07/11 00:00 [accepted]
PHST- 2022/08/15 03:43 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2022.922593 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2022 Jul 27;9:922593. doi: 10.3389/fcvm.2022.922593. 
      eCollection 2022.